Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:
“Hot Off The Press!
Just published in NEJM in conjunction with presentation at ASCO 2025.
Results of DeLLphi304 phase trial of Tarlatamab vs Chemotherapy in 2nd treatment for advanced Small Cell Lung Cancer.
mOS: 13.6 vs 8.3 months (HR: 0.6)
More Improvement in symptoms with Tarlatamab
≥ Grade 3 AEs: 54% vs 80%
CRS and ICANS mostly grade 1/2.”
Read OncoDaily’s special articles:
Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More